Sugammadex/Neostigmine and Liver Transplantation

• Status: Completed
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Cirrhotic patients undergoing liver transplantation are at very high risk of post operative complication such as post-operative residual curarization.

Rocuronium is a neuromuscular blocking agent that nowadays can be safely and rapidly antagonized with sugammadex.

No one study compared sugammadex versus neostigmine after rocuronium infusion during liver transplantation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Azienda Ospedaliera S. Maria della Misericordia
• Treatments: Neostigmine; Rocuronium

Criteria

Inclusion Criteria:

• American Society of Anesthesiology status (ASA) III

• Ability to give a written informed consent

• Liver transplantation

Exclusion Criteria:

• Any allergy to medications involved in the study

• Any disease involving neuromuscular transmission

• Any therapy with toremifene, flucloxacillin or fusidic acid

• Renal disease with glomerular filtration rate less than 30 ml/min/1.73m2

• Hyperthermia maligna

• Anticonceptional therapy

• Pregnancy

• Core body temperature less than 35°C or skin temperature less than 32°C at the end of surgery